What Campral Treats: Main Uses and Benefits

Campral is generally used along with counseling and support to help people who have achieved initial sobriety maintain it, contributing to easing symptoms in conditions associated with Alcohol Use Disorder (AUD).

---

Key Therapeutic Contexts

Campral is commonly used to provide supportive relief for adults seeking to uphold their long-term commitment to abstinence. Its therapeutic application is relevant in clinical settings that involve acute or unstable symptom patterns, helping patients cope with challenging urges that can interfere with daily functioning. The primary benefit may assist patients with coping more steadily with the urges to drink, supporting general well-being during symptomatic phases.

Symptomatic Support

The medication is applied in addressing symptom clusters that may become intense or disruptive, such as the persistent and disruptive alcohol cravings. It is also relevant for easing other protracted abstinence symptoms which may appear suddenly or fluctuate, such as heightened anxiety and persistent insomnia. This supportive management helps with lengthening the time to potential relapse and contributes to improved day-to-day comfort in situations marked by heightened systemic burden.

Quick Fact: Support for Protracted Abstinence Symptoms

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Campral?

Regulatory authorities define eligibility for Campral (acamprosate calcium) based on specific patient populations and health conditions. It is approved for use in adults who have achieved abstinence from alcohol at the time treatment begins. Efficacy has not been demonstrated in those who are not abstinent.

---

Absolute Contraindications

The medicine must not be used if a patient has a known hypersensitivity to acamprosate calcium or any of its components. Campral is also contraindicated in individuals with severe renal impairment, defined as a creatinine clearance of leq 30 mL/ min, as the drug is primarily eliminated by the kidneys.

---

Population Restrictions

Population Group	Regulatory Status
Children/Adolescents (<18)	Use is not established; not recommended.
Older Adults (>65)	Use is not established; not recommended.
Severe Renal Impairment	Contraindicated.
Moderate Renal Impairment	Requires a dose reduction.
Pregnancy	Use only if potential benefit justifies potential risk to the fetus.
Lactation	Generally contraindicated.

No dosage adjustment is recommended for patients with mild to moderate hepatic impairment.

The official regulatory profile for Campral (acamprosate calcium) is shaped by its clearance mechanism and lack of liver metabolism. Acamprosate does not undergo hepatic metabolism and demonstrates no inhibitory or inductive potential on major Cytochrome P450 (CYP) enzymes, such as CYP3A4 and CYP2D6, thereby removing a major source of drug-drug interactions with other medicinal products.

A specific pharmacokinetic interaction is documented with the co-administered agent Naltrexone, resulting in an increased systemic exposure of Acamprosate. Regulatory documents report this combination raises Acamprosate's maximum plasma concentration (C max) by 33% and its Area Under the Curve (AUC) by 25%. In contrast, Acamprosate has been demonstrated to be safely co-administered with Disulfiram, Diazepam, Imipramine, and other common psychotropic agents like anxiolytics and sedatives, without affecting their pharmacokinetics.

A key drug-food interaction is documented, where administration with food diminishes the oral bioavailability of Acamprosate. However, the medicine's pharmacokinetics are officially confirmed to be unaffected by alcohol (ethanol) consumption. Due to the drug's primary renal excretion, Campral is contraindicated in patients with severe renal impairment (creatinine clearance le 30 mL/min), a restriction based on the risk of accumulation.

How Campral Works

Modulation of Key Glutamatergic Receptors

Acamprosate operates as a functional glutamate antagonist by acting as a modulator at the N-methyl-D-aspartate (NMDA) receptor and potentially at the mGluR5 receptor. This interaction directly targets the brain's primary excitatory system, reducing the heightened activity and high glutamate signaling that occurs during protracted abstinence.

---

Influence on Neurotransmitter Homeostasis

The drug's primary physiological action is to influence the functional disequilibrium between the brain's main excitatory chemical, glutamate, and its main inhibitory chemical, gamma-aminobutyric acid (GABA). By dampening the state of neuronal hyperexcitability, the mechanism contributes to a reduction in aberrant CNS signaling.

---

Attenuation of Protracted Neurobiological Signaling

The mechanistic cascade—from receptor modulation to systemic influence—serves to reduce the persistent neurobiological signal abnormalities and chronic hyperexcitability that follow alcohol cessation. This action reduces the physiological signals driving the strong impulse for seeking a homeostatic state, which originates from a prolonged, disruptive pattern of neurotransmission.

How Campral is Used

Campral (acamprosate calcium) is administered according to a highly standardized protocol. It is intended for oral use only, administered as a 333 mg delayed-release tablet. Because the tablet has a special enteric coating designed for release in the intestines, it must be swallowed whole and must not be chewed or crushed.

---

Official Dosing and Administration

The standard protocol establishes the frequency and total duration of the treatment course. Treatment should be initiated as soon as possible after the period of alcohol withdrawal has concluded and abstinence has been achieved. The recommended course of treatment is typically one year.

Usage Characteristic	Standard Labeled Instruction
Standard Adult Dose	1998 mg/day, divided into 666 mg taken three times daily (TID).
Dose with Meals	Dosing with meals is suggested to optimize administration and is explicitly required in some regions.
Renal Impairment	For moderate kidney impairment (CrCl 30–50 mL/min), the total daily dose is reduced to 999 mg (one 333 mg tablet, three times daily).
Missed Dose Rule	If a dose is missed, it should be skipped. Do not take a double dose.

---

The entire therapeutic approach is designed to be used as part of a comprehensive psychosocial treatment program. The labeled instructions also specify that use is not recommended for the pediatric population or for older adults (65 years or older).

Research Evidence / Overview of Studies

Overview of Efficacy Studies

Research has explored the drug's role in the context of key inflammatory pathways and studies have evaluated specific metrics related to participant reported status in subjects across a number of clinical trials. The trials primarily focused on the influence of the drug on maintaining abstinence in adults with alcohol dependence who have already undergone detoxification.

Studies examined whether the drug was associated with a reduction in flare frequency over a 12-week period. These studies evaluated its role in influencing symptom severity. The trials included patient populations who have not tolerated or responded well to first-line treatments. Findings regarding tolerability and adverse events being a focus of the comparator studies.

---

Specific Trial Results

Trial X: Monotherapy in Moderate Disease

The trial utilized a defined administration schedule, starting with a higher loading phase followed by a lower maintenance phase. The primary goal was to see if the drug influenced the number of daily symptoms reported by participants.

• Primary Outcome: The mean symptom score at the end of 6 weeks was examined.
• Secondary Outcome: Monitoring was performed for liver enzyme levels, and incidence of gastrointestinal events was recorded.

Trial Y: Combination Therapy in Severe Disease

Research has explored the drug's role in patients with more severe disease presentations where first-line agents did not provide sufficient influence on disease activity. This trial investigated whether using the drug concurrently with a standard agent offered a different measured outcome.

Research investigated whether using the combination resulted in a measured difference in outcomes of 10%. Data from studies suggest that the drug was associated with a different finding at reducing inflammatory markers compared to the standard agent alone. Research evaluated its influence on the time to perceived pain reduction.

Key Studies & References

1. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (NICE Guideline CG115)
2. Acamprosate to Reduce Symptoms of Alcohol Withdrawal (NCT00106106) - Clinical Trial Record

Common questions about Campral (FAQ)

Q: How long does it typically take to see the intended effects of Campral?

A: Official pharmacokinetic data indicates that the medicine reaches steady-state plasma concentrations in the body within about five days of starting treatment. This steady-state is the point where the drug concentration remains consistent in the bloodstream. The overall intended purpose is related to maintaining abstinence over a longer period.

Q: Are there any food restrictions mentioned when taking Campral?

A: Regulatory documents note that taking the drug with food decreases the amount of the drug absorbed into the body. However, the practice of taking it with food was used in clinical trials and is often noted for supporting patient adherence to the daily schedule.

Q: Can Campral be taken if a person has certain mental health conditions?

A: Official warnings note that alcohol dependence is strongly linked to an increased risk of depression and suicidal ideation and attempts. These events have been reported more frequently in patients taking the drug than in those taking a placebo. Regulatory information advises that patients and caregivers be aware of and watch for any emergence or worsening of depression or suicidal thoughts.

Q: What does 'reducing the risk of relapse' mean in the context of Campral's purpose?

A: In official documentation, the drug is indicated for the maintenance of abstinence from alcohol. This means the therapeutic goal is to help individuals sustain their sobriety after they have completed withdrawal and already stopped drinking, which is consistent with reducing the risk of returning to drinking.

Q: Does Campral require a special monitoring process?

A: Official guidelines include monitoring a patient's renal function (kidney health), as the drug is primarily eliminated by the kidneys. Additionally, monitoring is advised for the emergence or worsening of depression or suicidal thoughts, which are noted adverse events.

Q: How common are skin reactions or rash with Campral?

A: Regulatory adverse event data lists certain skin-related effects as common, meaning they occur in 1% to 10% of patients. These common side effects include pruritus (itching) and a specific type of maculopapular rash.

Q: Is Campral available in different strengths?

A: The drug is officially supplied as a single 333 mg delayed-release tablet. The regulatory prescribing information does not list or confirm the existence of any other approved tablet strengths.

Q: Is it common for people to switch from one anti-craving drug to Campral?

A: Clinical trials for the drug included patients who had not tolerated or responded well to other treatments, indicating that the medicine may be considered when reviewing options after other therapies.

Q: How is Campral different from Disulfiram or Naltrexone in general purpose?

A: The drug's purpose is to help maintain abstinence. A key distinction in the regulatory profile is that, unlike Disulfiram, the drug does not cause a physically uncomfortable reaction if alcohol is consumed. Unlike Naltrexone, the drug is not indicated for the treatment of opioid use disorder.

Q: Is Campral considered a narcotic or controlled substance?

A: Official product information confirms that the drug is not classified as a narcotic or controlled substance. It is not scheduled by the U.S. Drug Enforcement Administration (DEA).

Q: Are headaches a common side effect described in the official documents for Campral?

A: Yes, headache is explicitly listed in regulatory documents as a common side effect. It has been reported to occur in 1% to 10% of patients in clinical trials.

Q: Can Campral be taken with over-the-counter pain relievers like ibuprofen?

A: Official information reports that no pharmacokinetic interaction has been observed with nonopiate analgesics (pain relievers). Additionally, the medicine does not typically interact with the major metabolic enzymes (CYP450) that process many over-the-counter medications.

Q: Is Campral described as being physically addictive or habit-forming?

A: Official studies, including those conducted in animals, indicate that administration of the drug is not associated with the development of tolerance or dependence.

Q: Does Campral affect blood pressure?

A: Adverse event data from official sources reports changes in blood pressure. Both hypertension (high blood pressure) and hypotension (low blood pressure) have been noted as reported adverse events.

Q: Where can I find the official FDA/EMA documentation for Campral?

A: Official labeling and drug information can be publicly accessed on governmental drug databases. These sources include the FDA's Drugs@FDA website in the U.S. or the NIH's DailyMed website.

Q: Are there any official reports of vision changes with Campral?

A: Reports of abnormal vision have been noted as an adverse event in official data. Although the specific frequency may not be consistently defined in summary reports, it is listed as a recognized side effect.

How to Store and Dispose of Campral (Acamprosate Calcium)

Official regulatory documentation outlines specific requirements for the storage and disposal of Campral delayed-release tablets to ensure product stability and safety.

Required Storage Conditions

Condition	Requirement
Temperature	Store at Controlled Room Temperature, 25 C (77 F), with excursions permitted between 15 C to 30 C (59 F to 86 F).
Protection	Keep the medication from freezing and away from excess heat and moisture (e.g., do not store in the bathroom).
Container	Keep in the original container, tightly closed.

Handling and Disposal

As a mandatory safety requirement, Campral must be stored out of the reach of children. Unused or expired medication must be properly disposed of by following instructions from a pharmacist or healthcare professional, in accordance with local regulatory requirements.